NASDAQ:TYME - Tyme Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tyme Technologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.25 0.00 (0.00 %) (As of 02/18/2020 02:43 AM ET) Add Compare Today's Range$1.23Now: $1.25▼$1.2950-Day Range$1.19MA: $1.53▼$1.9452-Week Range$0.92Now: $1.25▼$3.26Volume259,972 shsAverage Volume344,713 shsMarket Capitalization$153.55 millionP/E RatioN/ADividend YieldN/ABeta0.4 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TYME Previous Symbol CUSIPN/A CIK1537917 Webhttp://www.tymeinc.com/ Phone212-461-2315Debt Debt-to-Equity RatioN/A Current Ratio2.32 Quick Ratio2.32Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book13.89Profitability EPS (Most Recent Fiscal Year)($0.32) Net Income$-32,980,000.00 Net MarginsN/A Return on Equity-341.27% Return on Assets-150.85%Miscellaneous Employees11 Outstanding Shares122,840,000Market Cap$153.55 million Next Earnings Date6/10/2020 (Estimated) OptionableOptionable Receive TYME News and Ratings via Email Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TYME Rates by TradingView Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions What is Tyme Technologies' stock symbol? Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME." How were Tyme Technologies' earnings last quarter? Tyme Technologies Inc (NASDAQ:TYME) issued its quarterly earnings data on Monday, November, 4th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.02. View Tyme Technologies' Earnings History. When is Tyme Technologies' next earnings date? Tyme Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, June 10th 2020. View Earnings Estimates for Tyme Technologies. What price target have analysts set for TYME? 1 analysts have issued twelve-month price objectives for Tyme Technologies' shares. Their forecasts range from $9.50 to $9.50. On average, they expect Tyme Technologies' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 660.0% from the stock's current price. View Analyst Price Targets for Tyme Technologies. What is the consensus analysts' recommendation for Tyme Technologies? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tyme Technologies. What are Wall Street analysts saying about Tyme Technologies stock? Here are some recent quotes from research analysts about Tyme Technologies stock: 1. According to Zacks Investment Research, "Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body's immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. " (1/11/2020) 2. HC Wainwright analysts commented, "We maintain our Buy rating of TYME and our 12-month price target of $9.50 per share. We derive our price target based on a net present value analysis of projected SM-88 revenues through FY2030, assuming a 12% discount rate and 2% terminal growth rate." (8/12/2019) Has Tyme Technologies been receiving favorable news coverage? Media coverage about TYME stock has trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tyme Technologies earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Tyme Technologies. Are investors shorting Tyme Technologies? Tyme Technologies saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 7,830,000 shares, an increase of 16.3% from the January 15th total of 6,730,000 shares. Based on an average trading volume of 511,300 shares, the short-interest ratio is currently 15.3 days. Approximately 19.0% of the shares of the stock are sold short. View Tyme Technologies' Current Options Chain. Who are some of Tyme Technologies' key competitors? Some companies that are related to Tyme Technologies include Atreca (BCEL), Urogen Pharma (URGN), Kadmon (KDMN), ZIOPHARM Oncology (ZIOP), AC Immune (ACIU), Kura Oncology (KURA), Crinetics Pharmaceuticals (CRNX), Neoleukin Therapeutics (NLTX), Molecular Templates (MTEM), Assembly Biosciences (ASMB), Axovant Sciences (AXON), CytoDyn (CYDY), Prothena (PRTA), Clovis Oncology (CLVS) and Milestone Pharmaceuticals (MIST). What other stocks do shareholders of Tyme Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include OpGen (OPGN), Karyopharm Therapeutics (KPTI), Bausch Health Companies (BHC), Rigel Pharmaceuticals (RIGL), AcelRx Pharmaceuticals (ACRX), Nabriva Therapeutics (NBRV), vTv Therapeutics (VTVT), Aduro BioTech (ADRO), Catalyst Pharmaceuticals (CPRX) and MEI Pharma (MEIP). Who are Tyme Technologies' key executives? Tyme Technologies' management team includes the folowing people: Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 56)Mr. Ben R. Taylor, Pres & CFO (Age 42)Mr. Michael S. Demurjian, Co-Founder, Exec. VP, COO & Director (Age 52)Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 55)Dr. Giuseppe Del Priore, Chief Medical Officer (Age 57) Who are Tyme Technologies' major shareholders? Tyme Technologies' stock is owned by a number of of retail and institutional investors. Top institutional investors include Healthcare Value Capital LLC (1.77%), State Street Corp (1.23%), UBS Group AG (0.07%), Barclays PLC (0.05%), Goldman Sachs Group Inc. (0.03%) and Ladenburg Thalmann Financial Services Inc. (0.02%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Douglas A Michels, Michael Demurjian, Michele Ilene Korfin and Steve Hoffman. View Institutional Ownership Trends for Tyme Technologies. Which institutional investors are selling Tyme Technologies stock? TYME stock was sold by a variety of institutional investors in the last quarter, including Healthcare Value Capital LLC and State Street Corp. View Insider Buying and Selling for Tyme Technologies. Which institutional investors are buying Tyme Technologies stock? TYME stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Barclays PLC, Ladenburg Thalmann Financial Services Inc., Renaissance Technologies LLC, Goldman Sachs Group Inc. and Citigroup Inc.. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, Michele Ilene Korfin and Steve Hoffman. View Insider Buying and Selling for Tyme Technologies. How do I buy shares of Tyme Technologies? Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Tyme Technologies' stock price today? One share of TYME stock can currently be purchased for approximately $1.25. How big of a company is Tyme Technologies? Tyme Technologies has a market capitalization of $153.55 million. The company earns $-32,980,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe.View Additional Information About Tyme Technologies. What is Tyme Technologies' official website? The official website for Tyme Technologies is http://www.tymeinc.com/. How can I contact Tyme Technologies? Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected] MarketBeat Community Rating for Tyme Technologies (NASDAQ TYME)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 179 (Vote Outperform)Underperform Votes: 190 (Vote Underperform)Total Votes: 369MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote "Outperform" if you believe TYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2020 by MarketBeat.com StaffFeatured Article: What is a support level?
